5e5 of anti-MSLN CAR-293 cells were stained with 100 μL of 3 μg/mL of AF555-Labeled Human Mesothelin (296-580), His Tag (Cat. No.MSN-HA2H8) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). AF555 signal was used to evaluate the binding activity (QC tested).
Anti-human MSLN mAb (chimeric mouse-human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface, can bind RFP Fusion Human Mesothelin (296-580), His Tag (Cat. No. MSN-HR2P4) with an affinity constant of 0.304 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Anti-human MSLN MAb (chimeric mouse-human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface, can bind GFP Fusion Human Mesothelin (296-580), His Tag (Cat. No. MSN-HG2P4) with an affinity constant of 0.542 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| RNA-Meso-CIR-T | RNA-Meso-CIR-T | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Mesothelioma | Details |
| Anti-mesothelin CAR-T (Pregene) | Clinical | Pregene (Shenzhen) Biotechnology Co Ltd | Hydrothorax | Details | |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
| KD-021 | KD-021 | Phase 1 Clinical | Neoplasms | Details | |
| PM-3006 | PM-3006 | Phase 1 Clinical | Biotheus Inc | Details | |
| LCAR-M23 | Nanjing Legend Biotechnology Co Ltd | Details | |||
| Inezetamab | AMG-994 | Amgen Inc | Details | ||
| Autologous Mesothelin-specific TCR-T Cell Therapy (Lonza Walkersville) | Phase 1 Clinical | Pancreatic Neoplasms | Details | ||
| Anti-MESO CAR-T cell(Ruijin Hospital) | Ruijin Hospital, Shanghai Jiaotong University School Of Medicine | Neoplasms | Details | ||
| BMS-986148 | BMS-986148 | Bristol-Myers Squibb Company | Details | ||
| anti-mesothelin thorium-227 labeled antibody chelator conjugate | BAY-2287411 | Bayer AG | Details | ||
| RG-7600 | RG-7600; DMOT-4039A | Genentech Inc | Details | ||
| anti-MESO CAR-T cells (Zhejiang University) | Zhejiang University | Details | |||
| ABBV-428 | ABBV-428; ABBV428 | Abbvie Inc | Details | ||
| Gavocabtagene autoleucel | TC-210 | Tcr2 Therapeutics | Details | ||
| iCasp9M28z | iCasp9M28z | Memorial Sloan Kettering Cancer Center | Details | ||
| Amatuximab | MORAb-009; MORAB-009-006 | National Cancer Institute | Details | ||
| CART-meso | CART-meso | Novartis Pharma Ag, University Of Pennsylvania | Details | ||
| RC-88 | RC-88 | Phase 2 Clinical | RemeGen Co Ltd | Solid tumours | Details |
| Anti-mesothelin CAR T cell therapy (Shanghai GeneChem) | Shanghai Genechem Co Ltd | Details | |||
| Anti-mesothelin CAR-NK cell therapy(Guojianchengnuo) | ALF-101 | Phase 1 Clinical | Guojianchengnuo Biotechnology (Beijing) Co Ltd | Carcinoma, Ovarian Epithelial | Details |
| Anetumab ravtansine | BAY-94-9343; BAY-94-9343-SPDB-DM4; Anti-mesothelin antibody-drug conjugate BAY 94-9343 | Phase 1 Clinical | Bayer AG, Morphosys | Ovarian Neoplasms; Neoplasms; Pancreatic Neoplasms; Mesothelioma | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax 
